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Accepted 20 January 2016Extracavitary primary effusion lymphoma (ExPEL) is a rare, high-grade lymphoproliferative disorder that dis-
plays immunoblastic, plasmablastic, or anaplastic morphology. It usually lacks expression of B-cell and T-cell
markers, but often expresses the plasma cell markers CD138 and MUM1, and the activation marker CD30,
along with EMA. ExPEL, similar to classic PEL occurring as lymphomatous effusions in serous body cavities with-
out an associated tumor mass, is consistently associated with human herpes virus-8 (HHV8) infection, while a
majority of cases also exhibits Epstein–Barr virus (EBV) co-infection. Clinically, it is characterized by an almost
exclusive male predominance (98% male), HIV-positivity (96% of patients are HIV+), acute presentation with
B symptoms, and unfavorable overall survival (40% of patients diewithin 2 months).We report an asymptomatic
HIV-negative female patient with incidentally found splenomegaly and extensive PET FDG-avid retroperitoneal,
pelvic, and mediastinal lymphadenopathy. A core biopsy of her right pelvic lymph node showed aggregates of
atypical cells with anaplastic features. Immunohistochemistry revealed that the neoplastic cells were positive
for CD45, CD20, CD30, MUM1, CD138, EMA, CD3, HHV-8 and EBER. The diagnosis of ExPEL was established.
Against medical advice and given the absence of signiﬁcant symptoms, the patient refused to start treatment.
Fourmonths after the diagnosis, the patient remains asymptomatic, and follow-up CT scandemonstrates stability
of her lymphadenopathy. We present here a case of ExPEL in which the patient's presentation deﬁes the clinical
norms, illustrating that ExPEL should also be included in the differential diagnosis of lymphomas occurring in
asymptomatic HIV-negative patients.
Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Primary effusion lymphoma (PEL) is a rare, aggressive B-cell lym-
phoproliferative disorder that is seen primarily inHIV+or other immu-
nodeﬁcient patients. It accounts for approximately 4%of all AIDS-related
lymphomas, but only for 0.3% of aggressive lymphomas in HIV-negative
patients [1]. In the absence of immunodeﬁciency, PEL has been reported
in older individuals primarily fromHHV8-endemic locations such as the
Mediterranean littoral [2]. Classic PEL presents most frequently as lym-
phomatous effusions in serous body cavities (pleural, pericardial, peri-
toneal), without an associated tumor mass. The tumor cells in PEL are
large, and manifest varied morphology, including immunoblastic,
plasmablastic, and anaplastic cells. PEL is a B-cell neoplasm, demonstra-
ble by the presence of monoclonal immunoglobulin geneedicine Service, Veteran Affairs
ermont St, Denver, CO 80220.
), pbhargav@bidmc.harvard.edu
ss article under the CC BY-NC-ND licrearrangement [3], but usually lacking pan B-cell markers, including
CD19, CD20, and CD79a, as well as surface and cytoplasmic immuno-
globulin light chain expression. Furthermore, there is evidence to sug-
gest that the neoplastic cells in PEL are of post-germinal center B-cell
derivation, asmost PELs evince somatic hypermutation of immunoglob-
ulin variable region genes, also expressing plasma cell markers, such as
CD138. Gene expression proﬁling analysis of PELs from HIV+ patients
shows that the neoplastic cells harbor molecular features most similar
to multiple myeloma and EBV-transformed lymphoblastic lymphoma
cell lines, indicating a pre–plasma cell or “plasmablastic” proﬁle [4].
Extracavitary primary effusion lymphoma (ExPEL), also known as
solid PEL, presents as a tumor mass, most commonly involving lymph
nodes, and, less frequently, solid organs and other tissues, without evi-
dence of effusion. By one report, lymph nodes are involved in 58% of
cases, and approximately half of those with nodal disease also harbor
concurrent disease at one or more extracavitary sites. Extranodal sites
that may be involved include the gastrointestinal tract, spleen, skin,
and liver [5]. This extracavitary/solid presentation of PEL may precede
or follow a typical case of PEL, or be the only site of involvement [6].
The clinicopathologic features of ExPEL are generally similar to those
of classic PEL. These tumors occur predominantly in HIV+ menense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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similar morphology, immunophenotype, genotype, and HHV8 viral sta-
tus relative to classic PEL.
2. Clinical summary
A 29-year-old female emigrant to the United States from a central
African country presented to her primary care physician (PCP) for rou-
tine clinical check-up. Shewas asymptomatic and her review of systems
was within normal limits. A complete blood count showed normal
white blood cell (6.6 K/μL) and platelet counts (307 K/μL), while the he-
matocrit was low (28.8%), with a high red blood cell distribution width
(18.9%), which was thought to be due to iron deﬁciency. Her past med-
ical history was notable for syphilis. The patient reported that ovarian
cysts were discovered on examination and seen on pelvic ultrasound
6 years ago, and she had been followed clinically since then. As part of
the follow-up for ovarian cysts, a CT scan performed on 8/28/12 demon-
strated incidental splenomegaly, and extensive mediastinal, abdominal,
and pelvic lymphadenopathy concerning for lymphoma (Fig. 1). A sub-
sequent PET scan on 9/18/12 demonstrated uptake in the previously de-
scribed nodes. A core needle biopsy of the right pelvic lymph node was
performed for tissue diagnosis on 9/25/12. It demonstrated a high-
grade, HHV8+, EBV+ large-cell lymphoma (Fig. 2). A staging boneFig. 1. Summary of patient’s CAT scan. Enlarged right internal iliac lymph node* 6.8 x 4.1
cm, which displaced the bladder° into the left hemipelvis. There is also splenomegaly♦
of 17 cm. Abdominal CT: (1) External iliac lymph node, 4.2 × 2.3 cm;
(2) right external iliac lymph node, 4.1 × 2.6 cm; (3) right internal iliac lymph node*,
6.8 × 4.1 cm; other: the bladder° is displaced by the lymphadenopathy into the left
hemipelvis. There is splenomegaly♦ of 17 cm. Chest CT: (1) 2 left mediastinal
lymph node, 1.4 × 1.2 cm and 1.5 × 1.3 cm; (2) left para-aortic
lymph node measures 2.5 × 1.8 cm; (3) left para-aortic lymph node at the
level of the aortic bifurcation, 3.4 × 3.3 cm ; (4) right paracaval lymph node, 3.1 ×
2.5 cm; (5) right paracaval lymph node, 2.1 × 1.4 cm.marrow biopsy was negative. Of note, the patient tested negative for
HIV twice, by both serology and PCR. Screening for viral hepatitis B
and C was also negative. Her blood leukocyte differentials were within
normal limits on multiple occasions, while a serum protein electropho-
resis showed polyclonal hypergammaglobulinemia. There was no other
speciﬁc testing undertaken to exclude other primary or acquired immu-
nodeﬁciency disorders. The patient elected to forgo treatment second-
ary to social and ﬁnancial reasons. Despite this, she remained
asymptomatic and a follow-up CT scan performed three months after
the initial diagnosis demonstrated stability of the abdominal masses
with no increase in size. Her LDH levels, and liver and renal function
tests remained normal on multiple occasions.
2.1. Pathologic ﬁndings
2.1.1. Cytology of touch imprints
Tumor cells show prominent anaplastic features with large, pleo-
morphic nuclei and prominent nucleoli (Fig. 2A).
2.1.2. Histomorphology
Sections of the right pelvic lymph node core biopsy show diffuse
sheets of anaplastic cells, some with distinct cell borders (Fig. 2B–D).
The nuclei are large and highly pleomorphic, with one or several nucle-
oli, and the cytoplasm is abundant and amphophilic. Bi- and multi-
nucleated cells are seen, including some with ‘horse-shoe’-shaped nu-
clei. Frequent mitotic ﬁgures and apoptotic bodies are noted.
2.1.3. Immunohistochemistry
The neoplastic cells are immunoreactive for CD45 and have dim,
subset expression of B-cell marker CD20, but not CD79a. They co-
express CD30, MUM1, CD138 (subset), EMA, and are strongly and dif-
fusely positive for both HHV8 epitopes and Epstein–Barr virus encoded
RNA (EBER). They express T-cell markers CD3 and CD2 (dim subset),
and the cytotoxic protein granzyme B, but are negative for other pan
T-cell markers (CD5, CD7, CD4, CD8) and the cytotoxic protein perforin.
They are additionally negative for pancytokeratin (AE1.3, Cam5.2 cock-
tail), ALK-1, and for kappa and lambda light chain expression by in-situ
hybridization studies. See Fig. 3 and Table 1.
2.1.4. Molecular study
PCR studies identify a clonal B-cell gene rearrangement, while T-cell
receptor gamma chain gene rearrangement is negative.
Extracavitary primary effusion lymphoma (ExPEL) involves lymph
nodes, solid organs, and other tissues, without evidence of cavitary effu-
sion. It occurs predominantly in HIV+ men who often present with
acute symptoms. Although there are reported immunophenotypic dif-
ferences [ExPEL has lower frequency of expression of CD45 (74% versus
94%), CD30 (63% versus 76%), and EMA (57% versus 75%), but higher
frequency of expression of CD20 (17% versus 5%), CD79a (23% versus
5%) and CD138 (70% versus 38%)] [5]; ExPEL generally shows similar
morphology, immunophenotype, genotype, and HHV8 viral status to
classic PEL (Table 1). The malignant cells are large and exhibit a range
of appearances, from immunoblastic or plasmablastic cells to those
withmore-anaplastic characteristics. Their immunophenotype often re-
ﬂects that of a mature B-cell shifting toward terminal plasma cell differ-
entiation. Commonly expressed markers are plasma-cell-related
antigen CD138 (73% positive), activation marker CD30 (61% positive),
and epithelial membrane antigen (57% positive). The key diagnostic cri-
terion for PEL is the presence of HHV8 in the nuclei of the malignant
cells. Themost commonmethod for detectingHHV8-positivity is immu-
nohistochemical staining for the latent viral gene product, known as
latency-associated nuclear antigen (LANA-1). Despite the usual co-
infection with EBV as seen by in situ hybridization for EBV encoded
RNA (75% of cases are EBER positive), staining for latent membrane
protein-1 (LMP1) is often negative [7]. Although complex and recurrent
cytogenetic abnormalities have been identiﬁed in the tumor cells of
Fig. 2. A. Touch preparation of core biopsy, Giemsa stain (40×): The cells are mono-, bi- andmulti-nucleated, including somewith ‘horse-shoe’-shaped nuclei. The chromatin is vesicular
andmany cells haveprominent eosinophilic nucleoli. B andC. Low (10×) and highpower (40×) views of core biopsy,H&E:Multiple aggregates of large atypicalmononuclear cells present
in nodular-to-conﬂuent pattern with interspersed smaller, mature-appearing lymphocytes. The atypical cells are large in size, with abundant pale, ﬁnely granular eosinophilic cytoplasm.
D. Core biopsy, Wright–Giemsa (40×).
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netic abnormalities include trisomy 7, trisomy 12, and chromosomal ab-
errations of bands 1q21–25. Immunoglobulin genes are often
rearranged (82% of cases), and can be used to demonstrate a monoclo-
nal B cell population by molecular methods [9]. In our case, the diagno-
sis of ExPEL was established by the overall morphologic,
immunophenotypic, and molecular ﬁndings.
2.2. Differential diagnosis
ExPEL has to be differentiated from other lymphoproliferative disor-
ders that exhibit immunoblastic or plasmablastic or anaplastic mor-
phologies, including anaplastic large cell lymphoma (ALCL),
plasmablastic lymphoma (PBL), diffuse large B-cell lymphoma withFig. 3. A and B. Immunohistochemistry on core biopsy (40×). Tumor cells are positive for CD45immunoblastic morphology, ALK1+ large B-cell lymphoma (ALK1+
LBCL), and plasmablastic plasma cell myeloma (PCM). Other HHV8+
lymphoproliferative disorders must also be ruled-out, including
multicentric Castleman disease (MCD)-associated, HHV-8-positive
LBCL (LBL-MCD), and germinotropic lymphoproliferative disorder.
ALCL morphologic features include cells with anaplastic/pleomor-
phic morphology, horseshoe-shaped hallmark cells, and intrasinusoidal
involvement. Similar to ExPEL, most ALCLs exhibit strong positivity for
CD30 and EMA. Fortunately, these can be distinguished by their ALK1
reactivity and absence of CD138 and HHV-8 [3].
PBL is a large B-cell lymphomawith highest frequency inHIV+ indi-
viduals. It most often presents as a mass at mucosal sites, particularly in
the oral cavity [3,10]. The tumor cells are positive for plasma cellmarker
CD138. Unlike ExPELs, which tend to lack expression of surface and(LCA), CD20 (dim subset), CD30, CD138, MUM1 (not shown), EMA, CD3, HHV8 and EBER.
t1:1 Table 1
t1:2 Clinicopathologic comparison between our case and 55 cases of ExPEL reported.
t1:3 Literature (summary of 55
reported cases)
Our case
t1:4 Clinical features
t1:5 Male/female ratio 98% male Female
t1:6 HIV status 96% HIV+ HIV−
t1:7 Presentation Usually symptomatic Asymptomatic
t1:8 Prognosis 40% die within 2 months Alive at
4 months
t1:9 Morphology
immunohistochemistry
Anaplastic, immunoblastic or
plasmablastic
Anaplastic
t1:10 CD45 76% + +
t1:11 CD20 18% + +
t1:12 CD79a 24% + −
t1:13 Kappa immunostain 11% + −
t1:14 Lambda immunostain 31% + −
t1:15 CD3 27% + +
t1:16 CD138 73% + +
t1:17 MUM1 100% + +
t1:18 ALK1 100% - −
t1:19 CD30 61% + +
t1:20 EMA 57% + +
t1:21 Ki-67 + average 90% +
t1:22 HHV8 100% + +
t1:23 EBER 75% + +
t1:24 BCR gene rearrangement 82% + +
t1:25 TCR gene rearrangement 100%− −
t2:1Table 2
t2:2Demographic and clinical features of three HIV negative patients with ExPEL.
t2:3Feature Case 1 Case 2 Our case
t2:4Age/sex 75/M 52/M 29/F
t2:5HHV-8 related disease Negative Negative Negative
t2:6HHV8-viremia (cp/ml) 231,430 2850 4,981,027
t2:7EBV viremia (cp/ml) Negative 1074 19,140
t2:8CD4 cell (count/μl) 470 501 625
t2:9Stage (Ann Arbor) IVB IIIA IIIB
t2:10B symptoms Severe weight loss Absent Absent
t2:11Site of involvement LN, Waldeyer's ring, soft
tissue, spleen
LN,
spleen
LN,
spleen
t2:12Bulky disease Present Present Present
t2:13Major laboratory
abnormalities
t2:14Severe anemia
t2:15(hemoglobin b9 g/dL)
Negative Negative Negative
t2:16Thrombocytopenia
(b150 K/μl)
Negative Negative Negative
t2:17Coomb's test Negative Negative Negative
t2:18Abnormal serum LDH
(N294 IU/L)
Present Negative Negative
t2:19Hypoalbuminemia
(b3.2 g/dL)
Present Negative Present
t2:20Treatment CHOP CEOP None
t2:21Outcome (months) Dead (2) Alive (8) Alive (5)
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munoglobulin G. EBV infection is found in 60–75% of PBLs; however,
HHV8 is consistently absent [3].
Immunoblastic variant of DLBCL is characterized by the presence of
greater than 90% immunoblasts, which exhibit abundant cytoplasm
and a single, centrally located nucleolus. The lesional cells are usually
strongly positive for B-cell markers such as CD20, PAX5, and CD79a,
and are negative for ALK1 and HHV-8 [3].
ALK+ LBCL may show sinusoidal growth and plasmablastic differ-
entiation, including the expression of CD138, MUM1, and EMA. In con-
trast with ExPEL, however, it is negative for CD30 and HHV-8, and is
characteristically strongly positive for ALK1 [3].
Plasmablastic/anaplastic plasma cell myeloma has signiﬁcant mor-
phologic similarity to ExPEL, especially those with plasmablastic fea-
tures. However, their clinical presentations are quite different.
Plasmablastic/anaplastic plasma cell myeloma typically presents with
serum paraproteinemia and lytic bone lesions. The disease typically in-
volves bone marrow of patients without associated HIV, HHV8, or EBV
infection. By immunohistochemistry, myeloma cells express CD138
andMUM1, but not CD30 and CD45. Cytoplasmic light chains are gener-
ally detectable in the cells of plasmablastic/anaplastic plasma cell mye-
loma, in contrast to ExPEL [3].
LBL-MCD is an HHV8-driven lesion occurring in patients with or
without HIV, and mainly involves the lymph nodes and spleen [3]. By
histology, HH8+ plasmablasts are found in the mantle zones of atretic
secondary follicles admixed with normal plasma cells. While the
plasmablasts in LBL-MCD express high levels of cytoplasmic immuno-
globulin M, most cases of ExPEL lack cytoplasmic immunoglobulin. Ad-
ditionally, LBL-MCD is not associated with EBV, whereas ExPEL is
commonly co-infected with this virus.
Germinotropic lymphoproliferative disorder presents as localized
lymphadenopathy in immunocompetent patients, and in contrast to
other entities considered in the differential diagnosis of ExPEL, shows
a favorable response to chemo- or radiotherapy. Histologically, it is
characterized by HHV8+, EBV+ plasmablasts that preferentially in-
volve germinal centers of lymphoid follicles, forming conﬂuent aggre-
gates. The lesional cells in germinotropic lymphoproliferative disorder
are typically negative for B-cell antigens (CD20, CD79a) and the plasma
cell marker CD138, but exhibit kappa or lambda surface light chain and
contain cytoplasmic immunoglobulin. Interestingly, they usuallydemonstrate a polyclonal or oligoclonal pattern of immunoglobulin
gene rearrangement [3,11].3. Discussion
Based upon evidence from 55 reported cases of ExPEL [5,6], it is clear
that ExPEL is primarily a disease of HIV+ males, who usually present
with acute symptomatology, typically portending a poor prognosis.
Herein, we report a case of ExPEL in an asymptomatic HIV-negative fe-
male with incidentally found masses. HIV antibody and HIV viral load
were sent and found to be negative on two occasions. Against medical
advice, the patient refused treatment, but remained asymptomatic
four months after her initial diagnosis. We ask if this more-smoldering
course is reserved for cases of ExPEL occurring in HIV-negative patients.
A healthy immune system is perhaps constraining the neoplasm. Alter-
natively, it may be the case that nodal ExPEL is inherently less aggres-
sive. To the best of our knowledge, only two cases of nodal based
ExPELs occurring in HIV-negative subjects have been reported [12],
exhibiting similar immunophenotypic expression patterns relative to
our case (CD138+, MUM1+, HHV8+). We compare the demographic
and clinical features of our case with those two previously reported
cases (Table 2). In all three, the patients manifested HHV8 viremia,
with EBV viremia also detected in two cases, despite normal CD4+
cell counts in all instances. All patients presented with advanced stage
(stage III or IV), with bulky disease. Despite this, two of three patients
were asymptomatic and without major laboratory abnormalities. The
patient in case 1 died within 2 months, while the patients from case 2
and our case are alive at 8 months and 5 months, respectively. The
only major difference among the three patients was that an elevated
serum LDH was seen in case 1, perhaps connoting higher tumor cell
turnover and death. As such, an immunocompetence status, nodal dis-
ease, and serum HHV8 viral load level are likely not predictive of a
less aggressive form of ExPEL. A comparison of the immunohistochem-
ical stain results from the three nodal ExPELs from these HIV-negative
patients also does not reveal differential expression patterns that may
predict clinical behavior (Table 3). Finally, it must be noted that in
case 2 and our case, the follow-up period is short, and more-
prolonged clinical follow-upwill be necessary to ascertain if they indeed
behave in an indolent manner.
t3:1 Table 3
t3:2 Immunohistochemical stain patterns of three lymph node based ExPELs occurring in HIV-
t3:3 negative subjects.
t3:4 Immunohistochemistry Case 1 Case 2 Our case
t3:5 CD45 − + +
t3:6 CD20 − − +
t3:7 CD79a − − −
t3:8 IgK − − −
t3:9 IgL − − −
t3:10 CD3 + − +
t3:11 CD138 + + +
t3:12 MUM-1 + + +
t3:13 ALK-1 − − −
t3:14 CD30 + − +
t3:15 EMA + − +
t3:16 HHV8 + + +
t3:17 EBER − + +
t3:18 BCR gene rearrangement − − +
t3:19 TCR gene rearrangement − − −
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woman, illustrating the potential clinical, morphologic and
immunophenotypic variability of these tumors. While ExPEL is per-
ceived as primarily a poor-prognosis disease of HIV+ males who pre-
sents acutely, as we have seen, the clinical spectrum now includes an
occurrence in an asymptomatic HIV− female with incidentally found
masses. Awareness of the existence and diversity of ExPEL and assess-
ment for HHV8 infection are essential for the correct diagnosis. There-
fore, it is probably worthwhile to perform KSHV/HHV8 (LANA)
immunohistochemistry for any large cell lymphoma, with appropriate
morphologic (cells with immunoblastic, plasmablastic or anaplasticcharacteristics) and immunophenotypic attributes (CD138+/
MUM1+ and CD30+ without clear evidence for B-cell or T-cell line-
age), regardless of the patient's HIV status.
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